A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
收藏DataCite Commons2025-11-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005190/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).
提供机构：
Vivli
创建时间：
2020-02-04
